Golimumab

Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research[1][2][3].

Product Specifications

CAS Number

[476181-74-5]

Product Name Alternative

CNTO-148

UNSPSC

12352203

Hazard Statement

H334

Target

Apoptosis; Caspase; Interleukin Related; TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/golimumab.html

Purity

99.77

Solubility

H2O

Smiles

[Golimumab]

Molecular Weight

(146.94 kDa)

Precautions

P261-P284-P304+P340-P501

References & Citations

[1]Ueda N, et, al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α. Inflamm Bowel Dis. 2013 May;19 (6) :1224-31.|[2]Pavitrakar V, et, al. Amelioration of Cisplatin-induced Renal Inflammation by Recombinant Human Golimumab in Mice. Curr Pharm Biotechnol. 2022;23 (7) :970-977.|[3]Shealy DJ, et, al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs. 2010 Jul-Aug;2 (4) :428-39.